AMOEBA (EPA:AMEBA) - 2017 Interim Financial Report

Transparency directive : regulatory news

25/09/2017 17:40

PRESS RELEASE

2017 Interim Financial Report

Lyon, September 25st, 2017 - AMOEBA (FR0011051598 - AMEBA), a French company
that develops a biological biocide capable of eliminating waterborne bacterial
risk and wound care applications, announced today that it has published its
Interim Financial Report for 2017.

AMOEBA's shareholders are informed that the interim financial report for the
2017 financial year ending on December 31st, 2017), can be found at the company
website:

http://www.amoeba-biocide.com/en/
regulatories-information-and-financial-documents

This report includes:

- Interim Activity Report
- Condensed Interim Financial Statements
- Certification of the person responsible for the interim financial report
- Statutory Auditors' Review Report on the interim financial information

About AMOEBA:

AMOEBA group's objective is to become the global leader in eliminating
waterborne bacterial risk in water treatment and wound care applications. Our
solutions represent alternatives to chemical products widely used in the
cooling water treatment and the wound care market. In a global market for
chemical biocides estimated to be worth EUR 21 bn(1) AMOEBA is focusing on the
industrial cooling tower application estimated at EUR 1.7 bn(2). Similarly, in
a global wound care market estimated at EUR 15.2bn(3), AMOEBA is targeting the
chronic wound care market in the USA, estimated to be worth EUR 751 million(4).
The use of Willaertia magna C2c Maky in health care products will be subject to
FDA (Food and Drug Administration) clearance in the USA. AMOEBA's biological
biocide for water treatment, BIOMEBA, has not yet been granted marketing
authorization in the USA, Europe and Canada. AMOEBA is taking the required
regulatory steps to be granted marketing authorization in those regions for the
use of BIOMEBA in cooling water systems. Based in Chassieu (Lyon, France),
AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and
joined the CAC(r) Small index on 21st September 2015. More information on
www.amoeba-biocide.com.

(1) marketsandmarkets.com, "Wound Care Market by Product, Wound Type, End User
- Global Forecast to 2021," 2016.
(2): Amoéba data combined from the following sources: DRIRE 2013, Eurostat,
ARHIA 2013
(3) M. Diligence, "Wound Management: An $18.5 billion+ worldwide market in
2021," MedMarket Diligence, 10 June 2013. [Online]. Available:
https://blog.mediligence.com/2013/06/10/
wound-management-an-18-5-billion-worldwide-market-in-2021/
[Accessed 14 February 2017].
(4) BCC Research, "Markets for Advanced Wound Management Technologies,"
Wellesley, MA, 2017.

Contacts :

AMOEBA
Nathalie COMBROUSSE
Marketing Communication Manager
Tel. : +33 (0)4 81 09 18 15
nathalie.combrousse@amoeba-biocide.com

ACTIFIN
Ghislaine GASPARETTO
Financial Communication
Tel. : +33 (0)1 56 88 11 11
ggasparetto@actifin.fr

source : webdisclosure.com

AMOEBA's latest news

07/10/2024 17:45

AMOEBA (EPA:AMEBA) - 2017 Interim Financial Report

Transparency directive : regulatory news

AMOEBA's latest news

Other stories